Relmada Therapeutics (RLMD) Net Margin (2012 - 2023)
Relmada Therapeutics' Net Margin was -1998.46% in Q4 2023, up 1511.09 percentage points from -3509.55% a year earlier but down 333.46 percentage points from the prior quarter.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Net Margin (2012 - 2023) Analysis & Trends
For FY2023, Net Margin at Relmada Therapeutics came in at -1917.65%, up 5654.73 percentage points from FY2022.
- In earlier years, Net Margin was -7572.38% in FY2022 (+14761.06 pp) and -22333.44% in FY2021.
- Quarterly Net Margin has moved between -95591.41% (Q4 2021) and -1665.00% (Q3 2023) over five years.
- Compared with a year earlier, Net Margin has increased for five straight quarters, with an average year-over-year change of +24468.92 percentage points over the last five quarters.
- Per Business Quant data, RLMD's Net Margin in the three quarters before Q4 2023 was -1665.00% (Q3 2023), -1855.86% (Q2 2023) and -4866.05% (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 26.44% |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 0.83% |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 24.24% |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 28.01% |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 22.65% |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 16.30% |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 37.28% |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 29.27% |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 19.55% |
| 10 | Relmada Therapeutics | 473.10 Mn | -85.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,998.46% |
| Sep 30, 2023 | -1,665.00% |
| Jun 30, 2023 | -1,855.86% |
| Mar 31, 2023 | -4,866.05% |
| Dec 31, 2022 | -3,509.55% |
| Sep 30, 2022 | -14,821.12% |
| Jun 30, 2022 | -9,696.84% |
| Mar 31, 2022 | -12,620.63% |
| Dec 31, 2021 | -95,591.41% |
| Dec 31, 2020 | -9,257.73% |
| Sep 30, 2020 | -4,652.49% |
| Sep 30, 2019 | -9,677.96% |
| Mar 31, 2019 | -16,852.16% |
| Sep 30, 2017 | -177.67% |
| Jun 30, 2017 | -793,017.96% |
| Mar 31, 2017 | -418,920.51% |
| Jun 30, 2016 | -174,967.88% |
| Mar 31, 2016 | -239,046.27% |
| Jun 30, 2015 | -3,776,788.28% |
| Mar 31, 2015 | -106,945.77% |
API Access
Relmada Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();